Purpose: The optimal treatment of AIDS-related NHL (ARL) has yet to be defined. The purpose of this study was 1) to evaluate the efficacy and toxicity of the CNOP-regimen (cyclophosphamide, mitoxantrone, vincristine, and prednison) in combination with G-CSF; and 2) to study the effect of this regimen on HIV-1 viral replication.
Introduction
The prognosis of AIDS-related lymphoma (ARL) is poor: although with chemotherapy complete remission rates of 50%-60% have been reported, median survival in most studies is only six to eight months [1, 2] . Intensive treatment has been associated with a higher mortality, mostly because of opportunistic infections [3, 4] .
We performed a phase II trial in ARL with a CHOPlike regimen, substituting mitoxantrone for doxorubicin, because mitoxantrone has been shown to be effective in NHL [5] and less toxic in terms of nausea, cardiovascular morbidity and alopecia [6] . To reduce the high risk of infection in these patients with often limited bone marrow reserve, and to enable adherence to dose-intensity, G-CSF (granulocyte colony stimulating factor) was added. The effect of this regimen on p24 antigen as well as HIV-RNA levels, known prognostic markers of HIVrelated disease progression [7] , was studied.
Patients and methods
eligible. Exclusion criteria were: primary central nervous system lymphoma, Karnofsky performance score <50%; active opportunistic infection, severe neutropenia (<1.5 x 10 9 /l) or thrombocytopenia ( < 100 x 10 9 /l), unless caused by bone marrow infiltration, and severe hepatic or renal dysfunction. The protocol was approved by the Ethics Committee. All patients gave written informed consent.
Chemotherapy regimen
Cyclophosphamide, 750 mg/m 2 , mitoxantrone, 10 mg/m 2 and vincristine, 1.4 mg/m 2 i.v. on day 1, and oral prednisolone 50 mg/m 2 on day 1-5 were administered every three weeks for a total of 6 cycles. In case of neutrophils < 1.0 x 1O 9 /1 and/or platelets < 100 x 1O 9 /1 chemotherapy was postponed for one week; in case of persistent pancytopenia a 50% dose-reduction for cyclophosphamide and mitoxantrone was made. G-CSF (Neupogen, Amgen, Thousand Oaks, CA) was self-administered on day 3-12 (300 ug subcutaneously). Antiretroviral therapy (mostly zidovudine) was discontinued just prior to the first cycle of chemotherapy and resumed after stopping chemotherapy. CNS prophylaxis was given by intrathecal administration of methotrexate, 10 mg once weekly for six weeks. All patients received Pneumocystis carinii pneumonia prophylaxis.
Patients with objective progression were taken off study. Treatment outcome was evaluated on the basis of intention to treat. Toxicity was scored using standard NCI common toxicity criteria.
Patients
All HIV-1 seropositive patients in 1993 and 1994 with biopsy-proven, previously untreated stage II, III, IV and stage I 'bulky' NHL were
Laboratory methods
Blood was drawn every three to four days for a complete blood count, and every three weeks forp24 Ag, HIV RNA and CD4 cell counts. Only the 12 patients that werep24 antigenemic at baseline (n = 11) or became antigenemic during treatment (n = 1) for whom at least two time points were available are depicted in this graph. For nine of these patients, p24 antigen levels were measured at the time of progression. * P < 0.05 when compared to baseline value. (B) HIV-1 RNA load in copies/ml ( • ) . For 17 patients, samples were available at baseline and prior to the second cycle of chemotherapy. For 11 patients, also a third sample at the time of progression or the last available timepoint for patients in continued complete remission was available. For RNA copy numbers below the detection limit the amount of viral RNA was set at 1000 copies/ml. # The actual value in this patient was 3.1 x 10 6 RNA copies/ml.
Serum HIV-1 p24 antigen
HIV-1 p24 antigen was measured in real time in serum by a solid-phase sandwich-type enzyme immuno-assay (EIA, Abbott, Abbott Park, IL; sensitivity 10 pg/ml).
Serum HIV-1 RNA
HIV-1 RNA was quantified by quantitative nucleic acid sequencebased amplification (NASBA™, Organon Teknika, Boxtel, The Netherlands; sensitivity 1000 copies/ml) in one batch from frozen samples (stored at -70 °C).
Statistical analysis
Statistical analysis was performed using the Number Cruncher Statistical System (NCSS, Kaysville, UT). Two-sided statistical tests were used, and a /'-value of <0.05 was considered to represent statistical significance.
Results

Baseline clinical characteristics
The median age of the patients (20 homosexual males and one female) was 42 years (range 27-60). NHL was the AIDS-defining diagnosis in 17 patients, although 19 of 21 patients had CD4 cell counts below 0.2 x 10 9 /l. Twelve patients were on antiretroviral therapy. The median Karnofsky performance score was 80%. Seventysix percent of patients had stage III or IV disease. None of the patients had evidence of a meningeal localization in the cerebrospinal fluid.
All NHL were of intermediate or high-grade malignancy according to the Working Formulation; 19 were of B-cell and two were of T-cell lineage.
Outcome of treatment
A total of 63 cycles of chemotherapy was given. Only 11 of 21 patients (52%) received three or more cycles of chemotherapy. The response rate based on intention to treat was 43%: four complete (19%) and five partial remissions (24%). One of the complete responders relapsed after 60 days; the others died of HIV-related causes without evidence of lymphoma at the time of death (disease free survival: 60, 244, 278 and 640 days). Median survival for the whole group was only five months (range 25-640 days), whereas it was 8.7 months (243, 244, 278,640) for complete responders, 4.8 months (107-220) for partial responders and 3.6 months (25-360) for nonresponders (P > 0.1). The chance of obtaining a remission did not correlate with initial CD4 cell count, prior AIDS, performance score or HIV-RNA levels.
The cause of death was progressive NHL in 12 patients, two of whom developed a CNS relapse; perforation of the small intestine in two; stomach perforation (after salvage chemotherapy with DHAP) in one; septi-caemia in three (not related in time to CNOP-chemotherapy); wasting in two; and congestive heart failure (after DHAP) in one patient.
Treatment related to.xicity
Hematologic to.xicity 10 patients developed a nadir neutropenia below 1.0 x 10 9 /l in 16 of 63 chemotherapy cycles (25%); in 10 of these episodes (16%) the neutrophil count fell below 0.5 x 10 9 /l. The median duration of severe neutropenia was only three days (range 3-8). The platelet count fell below 100 x 10 9 /l in nine episodes, below 50 in two and below 10 in one. None of the patients had bleeding complications. Postponement of chemotherapy by one week was necessary in 15 cycles; dose-modifications had to be made in 11 cycles (17%): in six cases because of neutropenia and in five because of thrombocytopenia.
Infectious complications
Only one patient had an opportunistic infection (CMV colitis). One patient had bacterial sepsis (E. coli, S. viridans, and K. oxytoca), two had neutropenic fever requiring hospitalization (all cultures negative), and three had a localized infection (perianal abcess).
Other treatment-related complications
Two patients with extensive lymphomatous bowel infiltration had a bowel perforation and died of faecal peritonitis; one patient had severe pancreatitis after the second cycle, and one patient had corticosteroid-induced diabetes. No other toxicities greater than grade I were observed. (Figure la ) At least one p24 Ag level at baseline and at day 22 was available for 18 patients. At baseline/?24 Ag levels were below the detection limit in seven patients and remained negative in six. In individuals who werep24 antigenemic the geometric mean decreased from 32.3 pg/ml at baseline to 12.0 pg/ml at day 22 (P = 0.01) and 15.5 pg/ml at the end of treatment [P = 0.05). Decreases in p24 levels were seen both in patients with and without prior antiretroviral treatment.
Effect on HIV-lp24 antigen levels
Effect on HIV-1RNA levels HIV-1 RNA levels could be measured in 17 patients for whom at least two samples were available (Figure lb) . Before start of chemotherapy, HIV-1 RNA levels were above the detection limit in 15 of 17 patients. HIV-1 RNA levels either remained unchanged (n -8) or decreased significantly (0.6-2.1 log decrease, n = 6) in 14 of 17 patients (82%), and increased in three patients. The decrease between day 0 and day 22 (geometric mean 89,125 -* 58,884 copies/ml) was not statistically significant, and RNA levels returned to baseline at the end of treatment. There was no correlation between initial RNA levels and outcome of chemotherapy, occurrence of neutropenia or infection.
Discussion
The results of this trial with CNOP chemotherapy and G-CSF were disappointing, with a response rate of 43% and a median survival of five months. These results compare unfavourably to results of CHOP-chemotherapy both in non-HIV-infected (70%-80% CR) [10] and in HIV-infected individuals (CR rate 60%-70%) [11] , even though most patients had good performance scores and only a few had a history of prior AIDS. Judged by CD4 cell counts, however, our patient group was severely immunosuppressed. In a recent direct comparison of CHOP and CNOP in elderly patients with NHL, both complete remission rate and median survival were superior in patients treated with CHOP [12] . However, in a retrospective analysis of 18 ARL patients previously treated in our hospital with CNOP also a higher CR rate (41%) was found [13] , and mitoxantrone has shown activity in relapsed or refractory patients with ARL who previously received doxorubicin [14] .
This phase II trial does not allow conclusions as to the usefulness of adding G-CSF to chemotherapy. However, the rate of infections was low, and dose-adjustment was necessary in 17% of chemotherapy cycles whereas this had been necessary in 38% of the cycles in our retrospective analysis [13] .
In terms of HIV-1 viral replication the combination of chemotherapy with G-CSF was safe. Even though 12 patients were on antiretroviral therapy which was stopped during chemotherapy, HIV-1 p24 Ag levels either remained undetectable or decreased during treatment in 94% of patients. Changes in HIV-1 RNA load were less pronounced, and RNA copy numbers returned to baseline at the end of treatment. This difference in dynamics can partly be explained by the higher sensitivity of the RNA-assay, and changes in RNA copy numbers correlate better with clinical response to antiretroviral treatment [15] . In the study by Kaplan using CHOP with or without GM-CSF p24 Ag levels dropped to 18% of baseline at day 8 for all patiens, remained low in the non-GM-CSF treated group, but increased to a median of 243% at day 22 in the GM-CSF treated group. This is in line with the observation that GM-CSF but not G-CSF enhances viral replication in vitro [16] . Therefore, our observations imply that G-CSF can be used safely to sustain hematopoiesis in HIV-seropositive patients receiving anti-lymphoma chemotherapy. It should be noted, however, that with the advent of highly active combination antiretroviral therapy, the current policy in patients with ARL is to continue antiretroviral therapy in an attempt to restore immune function and thus to aid in obtaining or maintaining a remission of the lymphoma.
